Funder: National Institutes of Health

Due Dates: March 3, 2025 (New, Renewal, Resubmission, Revision) | July 28, 2025 (New, Renewal, Resubmission, Revision)

Funding Amounts: Up to $125,000/year (R21 phase, max 2 years); up to $250,000/year (R33 phase, max 3 years); total project period up to 5 years.

Summary: Supports functional validation and characterization of genes or variants implicated in substance use disorders using genome or epigenome editing, with resources made broadly available.

Key Information: Clinical trials are not allowed; generated genetic resources must be shared with the scientific community.